Australian Advisors Will Ponder Sandoz’ Pegfilgrastim And Pfizer’s Trastuzumab
A body that advises Australia’s Department of Health on reimbursement will in November consider listing applications for Sandoz’ Ziextenzo pegfilgrastim candidate and well as for Pfizer’s recently authorized Trazimera trastuzumab brand.
You may also be interested in...
Mylan and Biocon have launched their Fulphila biosimilar version of pegfilgrastim in Australia, marking the pair’s third local biosimilar launch under their partnership.
Merck Sharp & Dohme’s Ontruzant has become the fourth trastuzumab biosimilar to be reimbursed in Australia, while Pfizer’s Trazimera is in line to be the fifth.
Lamivudine combinations with zidovudine, as well as ezetimibe, bosentan and infliximab were among the drugs in the crosshairs for Australian reimbursement price cuts from 1 October.